MedPath

High Intensity Interval Versus Continuous Moderate Intensity Training: Maximizing the Benefits of Exercise in Overweight Adolescents

Not Applicable
Completed
Conditions
Metabolism
Physical Fitness
Interventions
Other: High Intensity Interval Training
Other: Moderate Intensity Training
Registration Number
NCT01935323
Lead Sponsor
University of Alabama at Birmingham
Brief Summary

6-week, single site, two parallel arm, randomized, controlled trial comparing the effectiveness of a High Intensity Interval Training (HIIT) versus a continuous Moderate Intensity Training (MIT) program on cardiovascular and metabolic health outcomes in overweight adolescent males. HIIT training may be a potent time-efficient strategy to induce similar metabolic and cardiovascular adaptations typically associated with MIT.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
30
Inclusion Criteria
  • Ages 17-22
  • Men
  • BMI (25.0 - 35.0 kg/m2)
  • Interested in improving health and fitness
Read More
Exclusion Criteria
  • Weight loss or gain of >10% of body weight in the past 6 months for any reason.
  • Currently taking medication that suppresses or stimulates appetite.
  • History of prior surgical procedure for weight control or liposuction.
  • Current smoker.

Any major disease, including:

  • Active cancer or cancer requiring treatment in the past 2 years (except nonmelanoma skin cancer).

  • Active or chronic infections, including self-reported HIV positivity and active tuberculosis.

  • Diagnosed heart conditions.

  • Uncontrolled hypertension: systolic blood pressure 160 mm Hg or diastolic blood pressure 95 mm Hg on treatment.

  • Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).

  • Asthma.

  • Diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dL), or use of any anti-diabetic medications.

    • Conditions or behaviors likely to effect the conduct of the trial: unable or unwilling to give informed consent; unable to communicate with the pertinent clinic staff; unwilling to accept treatment assignment by randomization; current or anticipated participation in another intervention research project that would interfere with the intervention offered in the trial; likely to move away from participating clinics before trial completed; unable to walk 0.25 mile in 10 minutes.
    • Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable (no change for 6 months).
    • Any active use of illegal or illicit drugs.
    • Excessive alcohol intake defined as an average consumption of 3 or more alcohol containing beverages daily.
    • Unwilling to limit alcohol intake to ≤2 drink per day (one drink = 4 oz. wine, 12 oz. beer, or ½ shot of liquor).
    • Current exerciser (>30 min organized exercise per week).
    • Indication of unsuitability of current health for exercise protocol (PARQ).
    • Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High Intensity Interval TrainingHigh Intensity Interval TrainingParticipants will perform the HIIT protocol on an electronically-braked cycle ergometer (Quinton Excalibur, Quinton Instrument Company, Bothell, WA). Participants will perform a 20-minute protocol, consisting of four minutes of cycling at 15% of maximum anaerobic power (Max-AP) followed by 30 seconds at 85% of Max-AP. These workloads will be based upon pre-trial Wingate tests. This cycle was repeated four times within each protocol, ending with two minutes at 15% of Max-AP. This will be performed 3d/wk for 6wks, with at least 24 hrs between each session.
Moderate Intensity TrainingModerate Intensity TrainingParticipants will perform 45-60 min (graduated over time to 60) of continuous cycling at 65% of VO¬2peak on a Monark cycle ergometer. Workload will be based upon pre-trial VO¬2peak testing. MIT exercise will be performed 5d/wk for 6wks.
Primary Outcome Measures
NameTimeMethod
Body Composition as measured by DXABaseline and 6 weeks
Secondary Outcome Measures
NameTimeMethod
GhrelinBaseline and 6 weeks
GlucoseBaseline and 6 weeks
AdiponectinBaseline and 6 weeks
Appetite/satiety measuresbaseline & 6 weeks

composite score

24-hour dietary recallpre-baseline, baseline, 6 weeks
HDL CholesterolBaseline and 6 weeks
Self Motivation Inventorybaseline and 6 weeks
Body WeightBaseline and 6 weeks
Blood PressureBaseline and 6 weeks
Peak uptake of volume of oxygenBaseline and 6 weeks
Wingate Cycle testBaseline and 6 weeks
Body Mass IndexBaseline and 6 weeks
LDL CholesterolBaseline and 6 weeks
TriglyceridesBaseline and 6 weeks
InsulinBaseline and 6 weeks
LeptinBaseline and 6 weeks
Free living energy expenditure as measured by accelerometerBaseline and 6 weeks
PYYBaseline and 6 weeks
Protein CarbonylsBaseline and 6 weeks

ELISA assay purchased from NW LifeSciences. Prior to analysis, all serum samples were assayed for protein concentration based on the methods of Bradford and adjusted to 4 mg・mL-1 protein using a phosphate buffer. Protein carbonyls, a measure of protein oxidation, were analyzed in duplicate in 50 μl of sera using a commercially available ELISA kit (NWK-PCK01).The intra- and interassay coefficients of variation were 2.7 % and 5%. The lower detection limit of the assay was 0.1 nmol/mg.

Quality & satisfaction with lifebaseline & 6 weeks

composite score

Rate of perceived exertion during exercise via Borg Scalebaseline and 6 weeks
IL-6Baseline and 6 weeks
TNF-alphaBaseline and 6 weeks
Total antioxidant capacityBaseline and 6 weeks
Profile of Mood Statesbaseline & 6 weeks

Trial Locations

Locations (1)

UAB Physiology Lab

🇺🇸

Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath